PLx Pharma Inc. PLXP
0.09 0.00 (+0.00%)
At closeApr 12, 2023, 4:00 PM EDT
0.0826 Day range 0.1555
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 1
- 2 months ago 1
- 3 months ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.28 | -0.28 – -0.28 | 0.10 | -380.0% | 700.00K | -56.0% | 1 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.39 | 0.0% | 800.00K | -61.6% | 0 |
| Current year | -1.39 | -1.39 – -1.39 | -2.06 | +32.5% | 3.70M | -54.9% | 1 |
| Next year | -1.10 | -1.10 – -1.10 | -1.39 | +20.9% | 3.50M | -5.4% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2022 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Aug 15, 2022 | Oppenheimer | Downgrade | Outperform | Perform |
| May 16, 2022 | Raymond James | Maintained | — | Outperform |
| Mar 14, 2022 | Raymond James | Maintained | — | Outperform |
| Dec 7, 2021 | Raymond James | Upgrade | Market Perform | Outperform |
| Sep 21, 2021 | BWS Financial | Initiated | — | Buy |
| Apr 9, 2021 | Oppenheimer | Initiated | — | Outperform |
| May 18, 2020 | JMP Securities | Maintained | — | Market Outperform |
| Mar 14, 2019 | JMP Securities | Initiated | — | Market Outperform |
| Jan 14, 2019 | Raymond James | Downgrade | Outperform | Market Perform |
| Mar 26, 2018 | Janney Capital | Downgrade | Buy | Neutral |
| Jan 19, 2018 | Janney Capital | Initiated | — | Buy |